美国慢性肾脏病患者的医疗资源利用及相关费用:DISCOVER CKD回顾性队列报告
基于DISCOVER CKD回顾性队列,链接LCED与TriNetX数据库,分析美国慢性肾脏病患者及肾功能下降但无慢性肾脏病人群的医疗资源利用与费用,按尿白蛋白肌酐比和估算肾小球滤过率分层;人均年总费用从A1的26,889美元至A3的42,139美元、从G2的28,627美元至G5的42,902美元,随肾功能下降而增加。
要点
- 人均年总费用A1为26,889美元、A3为42,139美元。
- 人均年总费用G2为28,627美元、G5为42,902美元。
- 合并心力衰竭者A3人均年费用50,191美元,商业保险者A3为55,735美元。
核心结论
- 慢性肾脏病及肾功能下降相关的医疗费用和资源利用对医疗系统和支付方构成沉重负担,并随慢性肾脏病进展而增加。
- 早期慢性肾脏病筛查尤其是尿白蛋白肌酐比筛查,配合主动疾病管理,可能改善患者结局并为医疗提供方显著节省医疗资源利用和费用。
研究设计与样本
- DISCOVER CKD回顾性队列研究,使用链接的有限索赔-电子病历数据集(LCED)和TriNetX数据库的门诊与住院数据。
- 纳入美国慢性肾脏病患者及估算肾小球滤过率60-75、尿白蛋白肌酐比<30的肾功能下降但无慢性肾脏病人群,排除有移植史或正在透析的患者。
主要发现
- 人均年总费用从A1的26,889美元至A3的42,139美元,从G2的28,627美元至G5的42,902美元,显示早期疾病负担已相当可观并随肾功能下降继续增加。
- 后期慢性肾脏病患者中,合并心力衰竭者A3人均年费用为50,191美元,商业保险覆盖者A3人均年费用为55,735美元。
关键数值与推荐
- 费用按尿白蛋白肌酐比和估算肾小球滤过率分层的慢性肾脏病严重程度进行分层。
- 肾功能下降但无慢性肾脏病定义为估算肾小球滤过率60-75且尿白蛋白肌酐比<30。
临床怎么用
- 原文结论提出早期慢性肾脏病筛查尤其是尿白蛋白肌酐比筛查,配合主动疾病管理,可能改善患者结局并为医疗提供方显著节省医疗资源利用和费用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: It is well established that chronic kidney disease (CKD) results in a significant burden on patients' health and health care providers. However, detailed estimates of the health care resource utilization (HCRU) of CKD are limited, particularly those which consider severity, comorbidities, and payer type. This study aimed to bridge this evidence gap by reporting contemporary HCRU and costs in patients with CKD across the US health care providers. METHODS: Cost and HCRU estimates of CKD and reduced kidney function without CKD (estimated glomerular filtration rate [eGFR]: 60-75 and urine albumin-to-creatinine ratio [UACR]: <30) were derived for US patients included in the DISCOVER CKD cohort study, using linked inpatient and outpatient data from the limited claims-EMR data set (LCED) and TriNetX database. Patients with a history of transplant or undergoing dialysis were not included. HCRU and costs were stratified by CKD severity using UACR and eGFR. RESULTS: Overall health care costs ranged from $26,889 (A1) to $42,139 (A3), and from $28,627 (G2) to $42,902 (G5) per patient per year (PPPY), demonstrating a considerable early disease burden which continued to increase with declining kidney function. The PPPY costs of later stage CKD were particularly notable for patients with concomitant heart failure ($50,191 [A3]) and those covered by commercial payers ($55,735 [A3]). CONCLUSIONS: Health care costs and resource use associated with CKD and reduced kidney function pose a substantial burden across health care systems and payers, increasing in line with CKD progression. Early CKD screening, particularly of UACR, paired with proactive disease management may provide both an improvement to patient outcomes and a significant HCRU and cost saving to health care providers.
引用
- Garcia Sanchez JJ, James G, Carrero JJ, et al. Health Care Resource Utilization and Related Costs of Patients With CKD From the United States: A Report From the DISCOVER CKD Retrospective Cohort. Kidney Int Rep. 2023. PMID: 37069994. doi:10.1016/j.ekir.2023.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。